Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. [electronic resource]
Producer: 20070612Description: 2218-24 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carboplatin -- administration & dosage
- Deoxycytidine -- administration & dosage
- ErbB Receptors -- analysis
- Female
- Humans
- Immunohistochemistry
- Male
- Middle Aged
- Paclitaxel -- administration & dosage
- Prospective Studies
- Receptor, ErbB-2 -- analysis
- Trastuzumab
- Urinary Bladder Neoplasms -- chemistry
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.